Schott Pharma stock heads into the open near its recent high
Published on 09/17/2026 at 05:34 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Schott Pharma stock closed at EUR 23.35 on the Frankfurt exchange on September 16, 2026, unchanged in percent versus the prior close and within a trading range between EUR 23.05 and EUR 23.35 for the session. Compared with the recent 52-week high of EUR 23.85 reached on September 15, 2026, the shares remained modestly below that level while holding onto strong gains in recent weeks.
September 16, 2026 in numbers
Schott Pharma AG & Co. KGaA (ISIN DE000A3ENQ51) saw its Frankfurt listing trade between an intraday low of EUR 23.05 and an intraday high of EUR 23.35 on September 16, 2026, with the closing price at EUR 23.35 matching the prior close, according to Frankfurt quote data. Per the same Frankfurt overview, the session turnover was limited, with only a small number of shares changing hands at that price level on September 16, 2026, underlining a calm trading day after a strong move earlier in the week.
In the broader market environment, Schott Pharma’s recent performance outpaced the German small-cap segment, with the stock’s position just below its 52-week high of EUR 23.85 on September 15, 2026 contrasted against a more muted pattern in the wider index backdrop. On September 16, 2026, major United States equity benchmarks such as the S&P 500 slipped, with the S&P 500 closing down about 0.4% at 7,551.81, illustrating a softer global equity tone that day while Schott Pharma’s Frankfurt quote held steady. As a result, Schott Pharma’s flat close on September 16, 2026 meant the shares slightly outperformed falling United States indices in that session.
Analyst support and today’s focus
The key driver behind Schott Pharma’s recent strength was fresh analyst coverage from JPMorgan in the prior days. As Finanzen reported on September 15, 2026, JPMorgan initiated coverage of Schott Pharma with an Overweight rating, which helped push the shares up by around 4.4% in off-exchange Tradegate trading on that day. Further details on the new coverage show that JPMorgan set a price target of EUR 27.10, according to a market wrap carried by Ad-hoc-news, underscoring the positive stance of the United States bank on the company.
Today, September 17, 2026, investors are set to carry this context into the new session. The JPMorgan Overweight call and the EUR 27.10 target remain fresh in the market narrative, and the shares still trade a few percent below their 52-week high of EUR 23.85, leaving room between the current Frankfurt close of EUR 23.35 and the analyst’s target level. Broader market cues from United States indices, which declined modestly on September 16, 2026 as the S&P 500 fell 0.4% to 7,551.81 per a summary from KRMG, may also shape the risk tone heading into today’s European and United States trading hours. No major company-specific events for Schott Pharma are indicated for September 17, 2026 in the latest available investor and news overviews, so the stock’s near-term path is likely to be influenced mainly by how markets digest the recent analyst upgrade and the broader sector and index developments through today’s session.
